Grifols SA (GRFS)
9.545
+0.48
(+5.24%)
USD |
NASDAQ |
Nov 14, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
Grifols Revenue (Quarterly): 1.972B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.972B |
| June 30, 2024 | 1.957B |
| December 31, 2023 | 1.906B |
| September 30, 2023 | 1.739B |
| June 30, 2023 | 1.814B |
| December 31, 2022 | 1.751B |
| September 30, 2022 | 1.552B |
| June 30, 2022 | 1.643B |
| June 30, 2021 | 1.629B |
| March 31, 2021 | 1.428B |
| December 31, 2020 | 1.561B |
| September 30, 2020 | 1.583B |
| June 30, 2020 | 1.524B |
| March 31, 2020 | 1.427B |
| December 31, 2019 | 1.507B |
| September 30, 2019 | 1.462B |
| June 30, 2019 | 1.423B |
| March 31, 2019 | 1.314B |
| December 31, 2018 | 1.395B |
| September 30, 2018 | 1.330B |
| June 30, 2018 | 1.310B |
| March 31, 2018 | 1.257B |
| December 31, 2017 | 1.258B |
| September 30, 2017 | 1.244B |
| June 30, 2017 | 1.244B |
| Date | Value |
|---|---|
| March 31, 2017 | 1.131B |
| December 31, 2016 | 1.185B |
| September 30, 2016 | 1.116B |
| June 30, 2016 | 1.122B |
| March 31, 2016 | 1.058B |
| December 31, 2015 | 1.163B |
| September 30, 2015 | 1.079B |
| June 30, 2015 | 1.096B |
| March 31, 2015 | 1.025B |
| December 31, 2014 | 1.146B |
| September 30, 2014 | 1.096B |
| June 30, 2014 | 1.115B |
| March 31, 2014 | 1.093B |
| December 31, 2013 | 946.34M |
| September 30, 2013 | 882.42M |
| June 30, 2013 | 910.57M |
| March 31, 2013 | 902.58M |
| December 31, 2012 | 857.99M |
| September 30, 2012 | 803.63M |
| June 30, 2012 | 834.65M |
| March 31, 2012 | 874.10M |
| December 31, 2011 | 794.98M |
| September 30, 2011 | 805.90M |
| June 30, 2011 | 538.72M |
| March 31, 2011 | 357.60M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.427B
Minimum
Mar 2020
1.972B
Maximum
Sep 2024
1.666B
Average
1.629B
Median
Jun 2021
Revenue (Quarterly) Benchmarks
| Cellectis SA | 16.20M |
| Adaptimmune Therapeutics PLC | 128.23M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 5.624M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 56.85M |
| Total Expenses (Quarterly) | 1.621B |
| EPS Diluted (Quarterly) | 0.0836 |
| Enterprise Value | 8.218B |
| Gross Profit Margin (Quarterly) | 40.53% |
| Profit Margin (Quarterly) | 2.88% |
| Earnings Yield | 3.32% |
| Operating Earnings Yield | 17.54% |
| Normalized Earnings Yield | 3.643 |